Eric Joseph
Stock Analyst at JP Morgan
(1.93)
# 3,211
Out of 5,014 analysts
122
Total ratings
38.55%
Success rate
-8.85%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $57.21 | +11.87% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $5.68 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.42 | +1,186.55% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.33 | -15.97% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $66.23 | +1.16% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.51 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.47 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $9.76 | +207.38% | 7 | Jan 29, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.80 | +141.38% | 5 | Jan 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $63 → $71 | $48.24 | +47.18% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $33.76 | +27.37% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $23.07 | +64.72% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $3.71 | +519.95% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.60 | +123.68% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $6.50 | +223.08% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $26.32 | +82.37% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $11.02 | -9.26% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.68 | +792.86% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.25 | +166.67% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.32 | +87.97% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $10.04 | +9.56% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $53.88 | -23.90% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $16.51 | +505.69% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.57 | +779.20% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.14 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $8.15 | +34.97% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.59 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.50 | +2,081.82% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $9.43 | +3,081.34% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.19 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.66 | +442.17% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.75 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $4.09 | +926.89% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.59 | +720.19% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.67 | +1,536.17% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $57.21
Upside: +11.87%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.68
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.42
Upside: +1,186.55%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.33
Upside: -15.97%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $66.23
Upside: +1.16%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.51
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $9.76
Upside: +207.38%
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.80
Upside: +141.38%
Revolution Medicines
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $48.24
Upside: +47.18%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $33.76
Upside: +27.37%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $23.07
Upside: +64.72%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $3.71
Upside: +519.95%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.60
Upside: +123.68%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $6.50
Upside: +223.08%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $26.32
Upside: +82.37%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $11.02
Upside: -9.26%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.68
Upside: +792.86%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.25
Upside: +166.67%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.32
Upside: +87.97%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $10.04
Upside: +9.56%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $53.88
Upside: -23.90%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $16.51
Upside: +505.69%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.57
Upside: +779.20%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.14
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.15
Upside: +34.97%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $13.59
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.50
Upside: +2,081.82%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $9.43
Upside: +3,081.34%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.19
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.66
Upside: +442.17%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $2.75
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $4.09
Upside: +926.89%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.59
Upside: +720.19%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.67
Upside: +1,536.17%